相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy
Ziyu Wang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Ebru Aydin et al.
FRONTIERS IN IMMUNOLOGY (2021)
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Agrima Mian et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Current Progress in CAR-T Cell Therapy for Hematological Malignancies
Donglei Han et al.
JOURNAL OF CANCER (2021)
Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
Sajad Yaghoubi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults
Ruo-Jing Li et al.
CLINICAL CANCER RESEARCH (2020)
An evaluation of glasdegib for the treatment of acute myelogenous leukemia
Xavier Thomas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
Peter A. Riedell et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Polatuzumab Vedotin: a New Target for B Cell Malignancies
Yun Choi et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes
Kyriaki Tzogani et al.
ONCOLOGIST (2020)
Design and discovery of boronic acid drugs
Jessica Plescia et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Rituximab biosimilars in hematologic malignancies: the need for a real-world approach
Pilar Nava-Parada et al.
FUTURE ONCOLOGY (2020)
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Shikha Kumari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Chao Xue et al.
CANCER CELL INTERNATIONAL (2020)
Isatuximab for the treatment of relapsed/refractory multiple myeloma
Paul G. Richardson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Hydroxamic acid hybrids as the potential anticancer agents: An Overview
Wenhua Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
Cisplatin: The first metal based anticancer drug
Sumit Ghosh
BIOORGANIC CHEMISTRY (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sezary Syndrome
Yvette L. Kasamon et al.
CLINICAL CANCER RESEARCH (2019)
Polatuzumab Vedotin: First Global Approval
Emma D. Deeks
DRUGS (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
Daniel R. Reed et al.
CANCER MANAGEMENT AND RESEARCH (2019)
An Overview of Monoclonal Antibodies
Virginia Bayer
SEMINARS IN ONCOLOGY NURSING (2019)
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G. Martin et al.
CELLS (2019)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Maura C. O'Leary et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Aviva C. Krauss et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj et al.
CLINICAL CANCER RESEARCH (2019)
Nitro-Group-Containing Drugs
Kunal Nepali et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
CAR T Cell Therapy for Hematological Malignancies
Xin Yang et al.
CURRENT MEDICAL SCIENCE (2019)
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Jan Philipp Bewersdorf et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
M. Picardi et al.
BLOOD ADVANCES (2019)
The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
Frank Lyko
NATURE REVIEWS GENETICS (2018)
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Emanuela Martino et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Role of TPMT and ITPA variants in mercaptopurine disposition
Tina Gerbek et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Venetoclax: A new wave in hematooncology
Jana Mihalyova et al.
EXPERIMENTAL HEMATOLOGY (2018)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Zinc binding groups for histone deacetylase inhibitors
Lei Zhang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
Guenter Krause et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK
Robert A. Watson et al.
BRITISH JOURNAL OF CANCER (2018)
Moxetumomab Pasudotox: First Global Approval
Sohita Dhillon
DRUGS (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential
Lu Gan et al.
BIOMARKER RESEARCH (2018)
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W. Flinn et al.
BLOOD (2018)
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Iman Abou Dalle et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
Acalabrutinib: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
The role of B cell antigen receptors in mantle cell lymphoma
Michael Fichtner et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
Vinay Prasad et al.
SEMINARS IN ONCOLOGY (2017)
Inotuzumab Ozogamicin: First Global Approval
Yvette N. Lamb
DRUGS (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael D. Amatangelo et al.
BLOOD (2017)
US FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2017)
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade A Key Player Against Various Cancers
Jian Guan et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Structural Chemistry of Human RNA Methyltransferases
Matthieu Schapira
ACS CHEMICAL BIOLOGY (2016)
Isocitrate dehydrogenase mutations in gliomas
Matthew S. Waitkus et al.
NEURO-ONCOLOGY (2016)
A review of blinatumomab, a novel immunotherapy
Matthew J. Newman et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy ininflammatory bowel disease
W. Moon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The recognition of ubiquitinated proteins by the proteasome
Guinevere L. Grice et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Multifunctional Abl kinases in health and disease
Aaditya Khatri et al.
JOURNAL OF CELL SCIENCE (2016)
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
Albiruni R. Abdul Razak et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Spotlight on ixazomib: potential in the treatment of multiple myeloma
Barbara Muz et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Hila Magen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee et al.
CLINICAL CANCER RESEARCH (2015)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
Panobinostat: First Global Approval
Karly P. Garnock-Jones
DRUGS (2015)
Ixazomib for the treatment of multiple myeloma
Massimo Gentile et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Boris Shor et al.
MOLECULAR IMMUNOLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ponatinib: Accelerated Disapproval
Justin F. Gainor et al.
ONCOLOGIST (2015)
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
A. Pardanani et al.
BLOOD CANCER JOURNAL (2015)
New dimension in therapeutic targeting of BCL-2 family proteins
Samaher Besbes et al.
ONCOTARGET (2015)
Orphan drug approvals of 2014: Europe and the United States
Peter Norman
EXPERT OPINION ON ORPHAN DRUGS (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia
Wanda L. Salzer et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALISTS FOR THE PRIX GALIEN USA AWARDS 2013 (2014)
Obinutuzumab: First Global Approval
Fiona Cameron et al.
DRUGS (2014)
US Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia
Firoozeh Alvandi et al.
ONCOLOGIST (2014)
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
Yaoyu Chen et al.
ONCOTARGETS AND THERAPY (2014)
Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs
Chong Wang et al.
NATURE COMMUNICATIONS (2014)
Asparaginase Erwinia chrysanthemi (Erwinaze®): A Guide to Its Use in Acute Lymphoblastic Leukemia in the USA
Gillian M. Keating
BIODRUGS (2013)
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
Jeffrey A. Silverman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Pomalidomide: First Global Approval
Shelley Elkinson et al.
DRUGS (2013)
CD30 expression in peripheral T-cell lymphomas
Elena Sabattini et al.
HAEMATOLOGICA (2013)
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
Tyler Davis et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Utility of Modeling and Simulation in Drug Development and Regulatory Review
Shiew-Mei Huang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
A. A. Chanan-Khan et al.
BLOOD CANCER JOURNAL (2013)
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
Albert Deisseroth et al.
CLINICAL CANCER RESEARCH (2012)
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2012)
Azacitidine A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia
Gillian M. Keating
DRUGS (2012)
A Step Toward More Accurate Dosing for Mercaptopurine in Childhood Acute Lymphoblastic Leukemia
Hussain Mulla et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
R. Swords et al.
LEUKEMIA (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Omacetaxine mepesuccinate for the treatment of leukemia
Theo Daniel Kim et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Doxorubicin pathways: pharmacodynamics and adverse effects
Caroline F. Thorn et al.
PHARMACOGENETICS AND GENOMICS (2011)
Analysis of anticancer drugs: A review
Susanne Nussbaumer et al.
TALANTA (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Marco Falasca
CURRENT PHARMACEUTICAL DESIGN (2010)
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fraser F. Fleming et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
K. E. Yen et al.
ONCOGENE (2010)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Cutaneous T-Cell Lymphoma: Roles for Chemokines and Chemokine Receptors
Xue-Song Wu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The proteasome: Overview of structure and functions
Keiji Tanaka
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Suzie J. Scales et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy
Dexin Kong et al.
CANCER SCIENCE (2008)
Recent Advances in the Development of Multi-Kinase Inhibitors
Martin Krug et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2008)
A pilot pharmacokinetic study of oral azacitidine
G. Garcia-Manero et al.
LEUKEMIA (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Decitabine and its role in the treatment of hematopoietic malignancies
Elizabeth R. Plimack et al.
LEUKEMIA & LYMPHOMA (2007)
Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs
Jeroen C. Verheijen et al.
DRUGS OF THE FUTURE (2007)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Tyrosine kinase inhibitors in cancer therapy
S Madhusudan et al.
CLINICAL BIOCHEMISTRY (2004)
Mouse CD20 expression and function
J Uchida et al.
INTERNATIONAL IMMUNOLOGY (2004)
Thalidomide and immunomodulatory drugs as cancer therapy
N Raje et al.
CURRENT OPINION IN ONCOLOGY (2002)
Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo
S Partida-Sánchez et al.
NATURE MEDICINE (2001)
Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex
M Orlowski et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Immunotherapeutic perspective for bispecific antibodies
AB van Spriel et al.
IMMUNOLOGY TODAY (2000)
分享论文
